South State Corp increased its holdings in Johnson & Johnson (NYSE:JNJ) by 5.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 151,117 shares of the company’s stock after purchasing an additional 8,070 shares during the quarter. Johnson & Johnson makes up approximately 2.2% of South State Corp’s holdings, making the stock its 4th largest holding. South State Corp’s holdings in Johnson & Johnson were worth $19,647,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Harding Loevner LP purchased a new position in shares of Johnson & Johnson during the second quarter valued at approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its holdings in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the last quarter. Mountain Capital Investment Advisors Inc purchased a new position in shares of Johnson & Johnson during the second quarter valued at approximately $124,000. Shine Investment Advisory Services Inc. purchased a new position in shares of Johnson & Johnson during the second quarter valued at approximately $177,000. Finally, Lenox Wealth Management Inc. lifted its holdings in shares of Johnson & Johnson by 1.7% during the second quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock valued at $193,000 after purchasing an additional 24 shares during the last quarter. 65.58% of the stock is currently owned by institutional investors.
Johnson & Johnson (JNJ) opened at $129.88 on Thursday. Johnson & Johnson has a 1-year low of $120.95 and a 1-year high of $148.32. The firm has a market cap of $348,930.00, a P/E ratio of 23.92, a P/E/G ratio of 2.21 and a beta of 0.74. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.59%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 61.88%.
In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the sale, the vice president now owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.19% of the company’s stock.
Several equities analysts have recently issued reports on JNJ shares. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 target price for the company in a report on Thursday, January 11th. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Jefferies Group set a $165.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Monday. Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a report on Wednesday, January 24th. Finally, Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Four research analysts have rated the stock with a sell rating, nine have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus price target of $146.26.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.